Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q1 EPS of ($0.74), $0.40 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $166.8 million versus the consensus estimate of $197.77 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.